Want to see HK:1513 full AI Analyst Report?

Livzon Pharmaceutical Group (1513) Price & Analysis

1 Followers

1513 Stock Chart & Stats

HK$25.96

HK$0.04(0.15%)

At close: Jul 28 4:00 PM EDT

HK$25.96

HK$0.04(0.15%)

Day’s Range― - ―

52-Week RangeHK$23.24 - HK$39.32

Previous CloseN/A

Volume286.26K

Average Volume (3M)553.85K

Market Cap

HK$29.06B

Enterprise ValueHK$18.93K

Total Cash (Recent Filing)HK$9.56B

Total Debt (Recent Filing)HK$2.89B

Price to Earnings (P/E)14.0

Beta0.78

Next Earnings

Aug 22, 2026

EPS Estimate

0.74

Next Dividend Ex-DateN/A

Dividend Yield6.33%

Share Statistics

EPS (TTM)2.21

Shares Outstanding299,807,130

10 Day Avg. Volume697,200

30 Day Avg. Volume553,853

Financial Highlights & Ratios

PEG Ratio8.43

Price to Book (P/B)1.65

Price to Sales (P/S)1.90

P/FCF Ratio9.02

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$29.00

Price Target Upside11.71% Upside

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)2.35

Revenue Forecast (FY)HK$12.12B

Bulls Say, Bears Say

Bulls Say

High ProfitabilitySustained high gross and operating margins indicate structural cost advantages and pricing power in core products. These margins support durable earnings generation, fund R&D and product development, and help maintain return on equity (~14–15%) even if top-line growth remains muted.

Conservative LeverageLow leverage provides balance-sheet flexibility to absorb shocks, fund capex or strategic investments, and sustain distributions. Conservative capital structure reduces refinancing and interest-rate risk, supporting steady operations and optionality for long-term capital allocation decisions.

Strong Free Cash FlowRobust and growing free cash flow that approximates reported earnings indicates high earnings quality and internal funding capacity. Reliable FCF enables reinvestment, product development, and shareholder returns without heavy external financing, strengthening long-term financial resilience.

Bears Say

Multi-year Revenue DeclineA persistent top-line decline reduces scale benefits and constrains long-term growth prospects. Even with healthy margins, shrinking revenues limit absolute profit growth, squeeze future investment capacity, and make sustaining historical returns harder without clear new growth drivers.

Weak Cash Conversion Vs EBITLow operating cash conversion versus operating profit suggests working-capital or timing volatility that can make cash flow less predictable. This variability can constrain consistent reinvestment, M&A or dividend policies despite solid reported profitability, raising execution risk.

Limited Balance-Sheet CatalystsA stable asset base amid slowing revenue implies fewer organic expansion opportunities driven by balance-sheet deployment. Absent revenue reacceleration or strategic deals, the company may struggle to generate fresh upside from its existing asset footprint over the medium term.

Livzon Pharmaceutical Group News

Livzon Pharmaceutical Schedules Board Meeting for Interim Results Review

An update from Livzon Pharmaceutical Group ( ($HK:1513) ) is now available. Livzon Pharmaceutical Group has scheduled a...

3d ago

Livzon Subsidiary’s Ankylosing Spondylitis Drug Application Accepted by China’s NMPA

Livzon Pharmaceutical Group ( ($HK:1513) ) just unveiled an announcement. Livzon MABPharm, a subsidiary of Livzon Pharmaceutical Group,...

2M ago

Livzon Wins NMPA Approval for Biosimilar Fertility Drug

An announcement from Livzon Pharmaceutical Group ( ($HK:1513) ) is now available. Livzon MAB Pharm, a subsidiary of...

2M ago

Livzon Pharmaceutical Wins Shareholder Backing for All 2025 AGM and 2026 Class Meeting Resolutions

An update from Livzon Pharmaceutical Group ( ($HK:1513) ) is now available. Livzon Pharmaceutical Group reported that its...

2M ago

Livzon Pharmaceutical Revamps Board and Affirms Director Independence

Livzon Pharmaceutical Group ( ($HK:1513) ) just unveiled an announcement. Livzon Pharmaceutical Group has completed a broad refresh...

2M ago

Livzon Pharmaceutical Outlines Board and Committee Structure in Governance Update

An update from Livzon Pharmaceutical Group ( ($HK:1513) ) is now available. Livzon Pharmaceutical Group has detailed the...

2M ago

Livzon Pharmaceutical Declares Final 2025 Dividend and Sets Hong Kong Payout Details

The latest announcement is out from Livzon Pharmaceutical Group ( ($HK:1513) ). Livzon Pharmaceutical Group Inc. has declared...

2M ago

Livzon Secures Controlling Stake in Vietnam’s Imexpharm After Tender Offer Completion

The latest announcement is out from Livzon Pharmaceutical Group ( ($HK:1513) ). Livzon Pharmaceutical Group has completed a...

3M ago

Livzon Gains Control of Vietnam’s Imexpharm in RMB 1.56 Billion Tender Offer

Livzon Pharmaceutical Group ( ($HK:1513) ) just unveiled an update. Livzon Pharmaceutical Group has disclosed the outcome of...

3M ago

Livzon Pharmaceutical Clarifies Independence of Key Board Directors

The latest announcement is out from Livzon Pharmaceutical Group ( ($HK:1513) ). Livzon Pharmaceutical Group has issued a...

3M ago

1513 FAQ

What was Livzon Pharmaceutical Group Inc Class H’s price range in the past 12 months?

Livzon Pharmaceutical Group Inc Class H lowest stock price was HK$23.24 and its highest was HK$39.32 in the past 12 months.

What is Livzon Pharmaceutical Group Inc Class H’s market cap?

Livzon Pharmaceutical Group Inc Class H’s market cap is HK$29.06B.

When is Livzon Pharmaceutical Group Inc Class H’s upcoming earnings report date?

Livzon Pharmaceutical Group Inc Class H’s upcoming earnings report date is Aug 22, 2026 which is in 13 days.

How were Livzon Pharmaceutical Group Inc Class H’s earnings last quarter?

Livzon Pharmaceutical Group Inc Class H released its earnings results on Apr 23, 2026. The company reported HK$0.756 earnings per share for the quarter, missing the consensus estimate of HK$0.837 by -HK$0.081.

Is Livzon Pharmaceutical Group Inc Class H overvalued?

According to Wall Street analysts Livzon Pharmaceutical Group Inc Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Livzon Pharmaceutical Group Inc Class H pay dividends?

Livzon Pharmaceutical Group Inc Class H pays a Annually dividend of HK$1.643 which represents an annual dividend yield of 6.33%. See more information on Livzon Pharmaceutical Group Inc Class H dividends here

What is Livzon Pharmaceutical Group Inc Class H’s EPS estimate?

Livzon Pharmaceutical Group Inc Class H’s EPS estimate is 0.74.

How many shares outstanding does Livzon Pharmaceutical Group Inc Class H have?

Livzon Pharmaceutical Group Inc Class H has 299,807,130 shares outstanding.

What happened to Livzon Pharmaceutical Group Inc Class H’s price movement after its last earnings report?

Livzon Pharmaceutical Group Inc Class H reported an EPS of HK$0.756 in its last earnings report, missing expectations of HK$0.837. Following the earnings report the stock price went down -0.212%.

Which hedge fund is a major shareholder of Livzon Pharmaceutical Group Inc Class H?

Currently, no hedge funds are holding shares in HK:1513

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Livzon Pharmaceutical Group Stock Smart Score

Neutral

Fundamentals

Return on Equity

6.33%

Trailing 12-Months

Asset Growth

3.72%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Livzon Pharmaceutical Group Inc Class H

Livzon Pharmaceutical Group Inc. (1513) is a pharmaceutical company engaged in the research, development, manufacturing, and commercialization of medicines and related healthcare products. Its operations span chemical drugs, biologics, and traditional Chinese medicine, with product lines that include finished dosage pharmaceuticals and other pharmaceutical/medical health products and services.

Livzon Pharmaceutical Group (1513) Earnings & Revenues

Historic Earnings Reports

1513 Stock 12 Month Forecast

Average Price Target

HK$29.00

▲(11.71% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"HK$22","29":"HK$29","36":"HK$36","25.5":"HK$25.5","32.5":"HK$32.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$29.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,25.5,29,32.5,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.96,26.193846153846156,26.427692307692308,26.661538461538463,26.895384615384614,27.12923076923077,27.363076923076925,27.596923076923076,27.83076923076923,28.064615384615387,28.298461538461538,28.532307692307693,28.766153846153845,{"y":29,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.96,26.193846153846156,26.427692307692308,26.661538461538463,26.895384615384614,27.12923076923077,27.363076923076925,27.596923076923076,27.83076923076923,28.064615384615387,28.298461538461538,28.532307692307693,28.766153846153845,{"y":29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.96,26.193846153846156,26.427692307692308,26.661538461538463,26.895384615384614,27.12923076923077,27.363076923076925,27.596923076923076,27.83076923076923,28.064615384615387,28.298461538461538,28.532307692307693,28.766153846153845,{"y":29,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.187,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.999,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":32.484,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.332,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":29.463,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26.761,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":27.117,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.385,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.854,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26.423,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.109,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.88,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":25.96,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >